Guy van Hazel

8.6k total citations · 2 hit papers
66 papers, 5.2k citations indexed

About

Guy van Hazel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Guy van Hazel has authored 66 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Guy van Hazel's work include Colorectal Cancer Treatments and Studies (27 papers), Cancer Treatment and Pharmacology (16 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). Guy van Hazel is often cited by papers focused on Colorectal Cancer Treatments and Studies (27 papers), Cancer Treatment and Pharmacology (16 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). Guy van Hazel collaborates with scholars based in Australia, United States and United Kingdom. Guy van Hazel's co-authors include Bruce N. Gray, Niall C. Tebbutt, John Zalcberg, Timothy Price, Dongsheng Tu, Christos S. Karapetis, Paul Moroz, Derek J. Jonker, Malcolm J. Moore and Chris J. O’Callaghan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Guy van Hazel

65 papers receiving 5.0k citations

Hit Papers

Cetuximab for the Treatment of Colorectal Cancer 2002 2026 2010 2018 2007 2002 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cetuximab for the Treatment of Colorectal Cancer
    2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. New England Journal of Medicine profile →
  2. Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
    2002 855 citations Chris Twelves, Guy van Hazel et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guy van Hazel Australia 26 3.7k 1.8k 1.1k 942 894 66 5.2k
Emmanuel Quinaux Belgium 18 4.2k 1.1× 1.3k 0.7× 1.1k 1.0× 625 0.7× 768 0.9× 37 4.9k
J. Załuski Poland 13 3.7k 1.0× 1.7k 0.9× 855 0.8× 816 0.9× 713 0.8× 23 4.5k
Florin Sirzén Sweden 18 3.6k 1.0× 2.6k 1.5× 1.1k 1.0× 1.1k 1.1× 505 0.6× 28 5.5k
M. Mueser France 10 3.8k 1.0× 1.9k 1.1× 779 0.7× 682 0.7× 464 0.5× 18 4.5k
Gérard Lledo France 27 5.8k 1.6× 2.3k 1.3× 1.6k 1.5× 1.7k 1.8× 652 0.7× 101 6.5k
Sabine Tejpar Belgium 28 4.1k 1.1× 1.9k 1.1× 929 0.9× 700 0.7× 807 0.9× 78 5.3k
Tamás Pintér Hungary 18 4.6k 1.2× 2.7k 1.5× 814 0.7× 563 0.6× 1.3k 1.5× 51 5.9k
Erika Hitre Hungary 21 4.4k 1.2× 1.5k 0.8× 811 0.7× 790 0.8× 985 1.1× 60 5.5k
Vladimir Moiseyenko Russia 33 5.6k 1.5× 4.1k 2.3× 500 0.5× 1.8k 1.9× 1.3k 1.4× 142 8.1k
Anatoly Makhson Russia 7 4.2k 1.1× 1.9k 1.1× 1.2k 1.1× 758 0.8× 698 0.8× 11 5.3k

Countries citing papers authored by Guy van Hazel

Since Specialization
Citations

This map shows the geographic impact of Guy van Hazel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy van Hazel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy van Hazel more than expected).

Fields of papers citing papers by Guy van Hazel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy van Hazel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy van Hazel. The network helps show where Guy van Hazel may publish in the future.

Co-authorship network of co-authors of Guy van Hazel

This figure shows the co-authorship network connecting the top 25 collaborators of Guy van Hazel. A scholar is included among the top collaborators of Guy van Hazel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy van Hazel. Guy van Hazel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Wasan, Harpreet, Guy van Hazel, Volker Heinemann, et al.. (2017). Overall survival in the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line SIRT in patients with mCRC. Annals of Oncology. 28. x43–x44. 1 indexed citations
4.
5.
6.
Hazel, Guy van, et al.. (2016). Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer. Journal of Medical Economics. 20(2). 193–199. 17 indexed citations
7.
Ferry, David, Paul Ruff, Radek Lakomý, et al.. (2013). Time Course of Adverse Events in the Velour Trial. Annals of Oncology. 24. iv36–iv36. 1 indexed citations
8.
Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350. 4 indexed citations
9.
10.
Tebbutt, Niall C., Michelle M. Cummins, T. Sourjina, et al.. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer. 102(3). 475–481. 92 indexed citations
11.
Chen, Weiwen, et al.. (2010). Outcomes from Combined Chemoradiotherapy in Unresectable and Locally Advanced Resected Cholangiocarcinoma. Journal of Gastrointestinal Cancer. 43(1). 50–55. 15 indexed citations
12.
Morris, M. J., Cameron Platell, Kieran McCaul, et al.. (2007). Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. International Journal of Colorectal Disease. 22(8). 887–895. 33 indexed citations
13.
Siena, Salvatore, Marc Peeters, Eric Van Cutsem, et al.. (2007). Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. British Journal of Cancer. 97(11). 1469–1474. 65 indexed citations
14.
Jonker, Derek J., Chris J. O’Callaghan, Christos S. Karapetis, et al.. (2007). Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine. 357(20). 2040–2048. 1413 indexed citations breakdown →
15.
Goldstein, D., Guy van Hazel, Nick Pavlakis, & Ian Olver. (2005). Selective Internal Radiation Therapy (SIRT) plus systemic chemotherapy with Irinotecan. A phase I dose escalation study. Journal of Clinical Oncology. 23(16_suppl). 3701–3701. 18 indexed citations
16.
Scheithauer, Werner, J McKendrick, S. Begbie, et al.. (2003). Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of Oncology. 14(12). 1735–1743. 222 indexed citations
17.
Moroz, Paul, James Anderson, Guy van Hazel, & Bruce N. Gray. (2001). Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. Journal of Surgical Oncology. 78(4). 248–252. 25 indexed citations
18.
Cocconi, Giorgio, David Cunningham, Eric Van Cutsem, et al.. (1998). Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.. Journal of Clinical Oncology. 16(9). 2943–2952. 181 indexed citations
19.
Byrne, Michael, et al.. (1989). Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. British Journal of Cancer. 60(3). 413–418. 27 indexed citations
20.
Byrne, Michael, et al.. (1983). Adjuvant immunotherapy with BCG in stage II malignant melanoma. Journal of Surgical Oncology. 23(2). 114–116. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emmanuel Quinaux Breakdown of academic impact, for papers by J. Załuski Breakdown of academic impact, for papers by Florin Sirzén Breakdown of academic impact, for papers by M. Mueser Breakdown of academic impact, for papers by Gérard Lledo Breakdown of academic impact, for papers by Sabine Tejpar Breakdown of academic impact, for papers by Tamás Pintér Breakdown of academic impact, for papers by Erika Hitre Breakdown of academic impact, for papers by Vladimir Moiseyenko Breakdown of academic impact, for papers by Anatoly Makhson
Rankless by CCL
2026